Track 1:Drug Design and development: Challenges

• Track 1-1Computer-Aided Drug Design

• Track 1-2Rational Drug Design Approach

• Track 1-3Novel Approach

• Track 1-4Carbon nano tubes (CNTS)

• Track 1-5Topical Drug Development

• Track 1-6Genetics in Drug Development

• Track 1-7BA assessment of formulations

• Track 1-8Phase zero trials

• Track 1-9Structure based strategies

• Track 1-10Carbon nano tubes (CNTS)

• Track 1-11Parallel drug designs

Track 2:BA Studies and Assessment

• Track 2-1Nutrient Bioavailability

• Track 2-2Absolute Bioavailability

• Track 2-3Relative Bioavailability

• Track 2-4Mineral Bioavailability- Micro and Macro

• Track 2-5Vitamins Bioavailability

• Track 2-6BA of Contaminants In Soils & Sediments

• Track 2-7Drug Absorption and Distribution

• Track 2-8Disposition studies

• Track 2-9Product design- Considerations

• Track 2-10Bio accessibility Factor

Track 3:Drug Metabolism

• Track 3-1Metabolite Pharmacological Effects

• Track 3-2Prodrugs and their active metabolites

• Track 3-3Metabolic pathway

• Track 3-4Phase I metabolism of drug: P450 (CYP450)Enzyme

• Track 3-5Phase I vs. Phase II Metabolism

• Track 3-6Food/herbal remedies- drug interaction

• Track 3-7Effects on microsomal enzyme system of the liver

• Track 3-8Biochemistry applications

• Track 3-9Plasma Concentrations and Drug Effects

• Track 3-10Drug Efficacy and toxicity

• Track 3-11Adverse drug reactions

Track 4:BE Studies and Assessment

• Track 4-1Bioequivalence Protocols : In vitro-In vivo correlation

• Track 4-2Dissolution Studies

• Track 4-3Drug-release studies

• Track 4-4Genetic Phenotyping

• Track 4-5Response of clinical studies

• Track 4-6BE of Narrow Therapeutic Index Drugs

• Track 4-7BE of Endogenous substances

• Track 4-8BE testing-Geographical considerations

• Track 4-9Documented standard operating procedures

• Track 4-10BE-Highly variable drugs and drug products

• Track 4-11BE -Strategies

• Track 4-12BE assessment of IR and MR products

• Track 4-13Alcoholic Beverage Effects on MR Drug Products

• Track 4-14Analysis of BA/BE by Oral vs Parenteral

Track 5:Pharmacology- PK & PD approach

• Track 5-1Pharmacodynamics

• Track 5-2Drug Interactions

• Track 5-3Solubility of poorly and high soluble drug

• Track 5-4Drug Therapy

• Track 5-5Bio analytical method

• Track 5-6Clinical Pharmacology

• Track 5-7Behavioural pharmacology

• Track 5-8Drug Safety and Efficacy

• Track 5-9Posology& Development

• Track 5-10Clinical toxicology

• Track 5-11Biomarkers

• Track 5-12Recent Biomedical Innovation

Track 6:Pharmaceutical Formulations

• Track 6-1Solid Dosage Form

• Track 6-2Topical Dosage form

• Track 6-3Parenteral Dosage form

• Track 6-4Rectal and nasal drug products

• Track 6-5Solutions and Other Solubilized Dosage Forms

• Track 6-6Study Design- Single Vs Multiple- Dose

• Track 6-7In Vitro Dissolution Testing

• Track 6-8Immediate-Release Products

• Track 6-9Modified-Release Products

• Track 6-10Immediate-Release Formulations

• Track 6-11Modified-Release Formulations

Track 7:Clinical Research Vs Clinical Trails

• Track 7-1Pre-clinical research/trail

• Track 7-2Clinical Trial Management

• Track 7-3Clinical research phase studies

• Track 7-4In Vitro and In Vivo studies

• Track 7-5Clinical Study Designs

• Track 7-6Research and Trials on AIDS / Cancer / Diabetes

• Track 7-7Bioequivalence Protocol

• Track 7-8Trial design: formulation development

• Track 7-9Efficacy and Effectiveness of the trail

• Track 7-10Role of Biomarkers

Track 8:Biowaivers: Criteria

• Track 8-1Waivers of Pharmaceutical Dosage Form

• Track 8-2Waivers of Dosage Form Proportionality

• Track 8-3Waiver for In vivo bioavailability or bioequivalence

• Track 8-4Biowaiver for SUPAC

• Track 8-5Waivers of In Vivo Study Requirements

• Track 8-6Waiver in Dissolutions

Track 9:BCS & IVIVC Based Biowaivers

• Track 9-1BCS biowaivers

• Track 9-2Preclinical and clinical testing for oral drug delivery

• Track 9-3Consideration of biowaiver extensions for BCS class III drugs

• Track 9-4In vitro diffusion cells for dissolution testing in formulation development

• Track 9-5Dissolution testing in drug formulation

• Track 9-6In vitro preclinical ADME/BCS testing

• Track 9-7In vitro drug product research

• Track 9-8Requirement of In Vivo BA or BE Data

Track 10:Biosimilars: Recent approches

• Track 10-1Biosimilars: Regulatory approach

• Track 10-2Cancer therapeutics

• Track 10-3Cardiovascular therapeutics

• Track 10-4Diabetes therapeutics

• Track 10-5Commercialization or globalization of biosimilars

• Track 10-6Plant produced biosimilar products

• Track 10-7Analytical strategies

• Track 10-8Adverse drug reactions with pharmaceutical products

Track 11:Drug Safety: Pharmacovigilance Scope

• Track 11-1Application of drug safety

• Track 11-2Role of pharma industries

• Track 11-3Regulatory Affairs

• Track 11-4Pharmacy Practices and its Challenges

• Track 11-5Topical and dermatological drug products

• Track 11-6Physiological factors affecting drug absorption

Track 12:Contract Research Organizations

• Track 12-1Paid Research Studies

• Track 12-2Paid Clinical Trials

• Track 12-3GCP Training

Track 13:Regulatory Requirements and Approaches

• Track 13-1WHO Approaches

• Track 13-2FDA Approach and regulations

• Track 13-3TGA and risk management approach

• Track 13-4Food-Effect Bioavailability and Fed Bioequivalence Studies

• Track 13-5European Guidelines

• Track 13-6OTC drug products

Track 14:Recent advancements in BA/BE Research

• Track 14-1Novel Drug Delivery Systems- BA/BE approach

• Track 14-2Role of Nanotechnology in enhancing BA

• Track 14-3Solid lipid nanoparticle role in study design

• Track 14-4Bioequivalence Approach for Narrow Therapeutic Index Drugs

• Track 14-5Comparative drug products (ANDA) bioavailability for generic

• Track 14-6Generic drugs: Current claims and future directions

• Track 14-7Pilot study: Design, analysis and Execution

• Track 14-8Global Nano safety—Regulation vs. innovation

• Track 14-9BA/BE Studies for Immediate-Release Solid Oral Dosage Forms

• Track 14-10Generic antibiotic drugs and controversies: TE

• Track 14-11Food-effect bioavailability and fed bioequivalence studies

• Track 14-12Scaling approach for BA/BE studies

• Track 14-13Bioequivalence analysis of highly variable drugs

• Track 14-14BA Study for cancer drugs

• Track 14-15Bioavailability - applied studies and advances in methodology

• Track 14-16Dissolution Specifications for Generic Products

Track 15:Pharmaceutical Industry: Entrepreneur Meet